On February 11, 2022, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for a new monoclonal antibody for the treatment of COVID-19 that retains activity against the omicron variant.
New monoclonal antibody therapy receives EUA for treatment of COVID-19
Feb 23, 2022 2:30:00 PM / by Practice Support Team posted in COVID-19, monoclonal antibodies
Statewide standing orders rescinded for ineffective monoclonal antibodies
Jan 27, 2022 8:08:57 AM / by Practice Support Team posted in COVID-19, monoclonal antibodies
On January 24, 2022, NC State Health Director, Dr. Betsey Cuervo Tilson, rescinded the statewide standing orders for the following due to the high prevalence of the Omicron variant of the SARS-CoV-2 virus in North Carolina for which these therapies are not an effective treatment:
